Literature DB >> 9618246

Transgenic A1 adenosine receptor overexpression markedly improves myocardial energy state during ischemia-reperfusion.

J P Headrick1, N S Gauthier, S S Berr, R R Morrison, G P Matherne.   

Abstract

A1 adenosine (A1AR) activation may reduce ischemia-reperfusion injury. Metabolic and functional responses to 30 min global normothermic ischemia and 20 min reperfusion were compared in wild-type and transgenic mouse hearts with approximately 100-fold overexpression of coupled cardiac A1ARs. 31P-NMR spectroscopy revealed that ATP was better preserved in transgenic v wild-type hearts: 53 +/- 11% of preischemic ATP remained after ischemia in transgenic hearts v only 4 +/- 4% in wild-type hearts. However, recovery of ATP after reperfusion was similar in transgenic (46 +/- 5%) and wild-type hearts (37 +/- 12%). Reductions in phosphocreatine (PCr) and cytosolic pH during ischemia were similar in both groups. However, recovery of PCR on reperfusion was higher in transgenic (67 +/- 8%) v wild-type hearts (36 +/- 8%), and recovery of pH was greater in transgenic (pH = 7.11 +/- 0.05) v wild-type hearts (pH = 6.90 +/- 0.02). Bioenergetic state ([ATP]/[ADP].[Pi]) was higher in transgenic v wild-type hearts during ischemia-reperfusion. Time to ischemic contracture was prolonged in transgenic (13.6 +/- 0.8 min) v wild-type hearts (10.4 +/- 0.3 min). Degree of contracture was lower and recovery of function in reperfusion higher in transgenic v wild-type hearts. In conclusion, A1AR overexpression reduces ATP loss and improves bioenergetic state during severe ischemic insult and reperfusion. These changes may contribute to improved functional tolerance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9618246     DOI: 10.1006/jmcc.1998.0672

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  9 in total

Review 1.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

2.  Differential Tissue-Specific Function of Adora2b in Cardioprotection.

Authors:  Seong-wook Seo; Michael Koeppen; Stephanie Bonney; Merit Gobel; Molly Thayer; Patrick N Harter; Katya Ravid; Holger K Eltzschig; Michel Mittelbronn; Lori Walker; Tobias Eckle
Journal:  J Immunol       Date:  2015-07-01       Impact factor: 5.422

3.  Functional studies in atrium overexpressing A1-adenosine receptors.

Authors:  J Neumann; U Vahlensieck; P Boknik; B Linck; H Lüss; F U Müller; G P Matherne; W Schmitz
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 4.  Purinergic signaling in myocardial ischemia-reperfusion injury.

Authors:  Yi Zhuang; Mei-Ling Yu; Sheng-Feng Lu
Journal:  Purinergic Signal       Date:  2022-03-07       Impact factor: 3.765

5.  Overexpression of A(3) adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts.

Authors:  Heather R Cross; Elizabeth Murphy; Richard G Black; John Auchampach; Charles Steenbergen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-06-20       Impact factor: 4.733

6.  Ischemic and pharmacological preconditioning induces further delayed protection in transgenic mouse cardiac myocytes over-expressing adenosine A1 receptors (A1AR): role of A1AR, iNOS and K(ATP) channels.

Authors:  Mohammed A Nayeem; G Paul Matherne; S Jamal Mustafa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-25       Impact factor: 3.000

7.  ATP splitting by half the cross-bridges can explain the twitch energetics of mouse papillary muscle.

Authors:  C Widén; C J Barclay
Journal:  J Physiol       Date:  2006-02-23       Impact factor: 5.182

8.  Pertussis toxin sensitive and insensitive effects of adenosine and carbachol in murine atria overexpressing A(1)-adenosine receptors.

Authors:  Joachim Neumann; Peter Boknik; G Paul Matherne; Amy Lankford; Wilhelm Schmitz
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

9.  Apyrase treatment of myocardial infarction according to a clinically applicable protocol fails to reduce myocardial injury in a porcine model.

Authors:  Jesper van der Pals; Sasha Koul; Michael I Götberg; Göran K Olivecrona; Martin Ugander; Mikael Kanski; Andreas Otto; Matthias Götberg; Håkan Arheden; David Erlinge
Journal:  BMC Cardiovasc Disord       Date:  2010-01-04       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.